Who Owns Nesina?
Nesina is owned by Takeda Pharmaceutical Company, Japan's largest pharmaceutical company, listed on the Tokyo Stock Exchange (4502) and as an ADR on the NYSE (TAK). Nesina is the brand name for alogliptin, a once-daily DPP-4 inhibitor approved by the FDA on January 25, 2013. US patent expiry opened the market to generic alogliptin, and multiple manufacturers now supply the molecule while Takeda retains the brand.
Nesina Timeline
GlobalOfficial Website
Who Owns Nesina?
- Parent Company: Takeda Pharmaceutical Company
- Ownership Type: Product line
- Company Type: Publicly Traded
- Stock Ticker: Tokyo Stock Exchange; New York Stock Exchange (ADR): 4502 (TSE); TAK (NYSE ADR)
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Nesina | Takeda Pharmaceutical Company | Product line |
Where to Buy
Disclosure: We may earn commission from purchases
Nesina on AmazonAdvertisement
History of Nesina
- Founded: 2013
- Founders: Takeda Pharmaceutical (internal development)
Alogliptin was discovered and developed by Takeda's research organization as a highly selective once-daily DPP-4 inhibitor. The FDA approved Nesina on January 25, 2013, making it the third DPP-4 inhibitor on the US market after Merck's Januvia and Bristol-Myers Squibb/AstraZeneca's Onglyza.
Takeda launched the product with two fixed-dose companions: Kazano, combining alogliptin with metformin, and Oseni, combining it with pioglitazone, Takeda's own Actos molecule. In Europe the drug was marketed as Vipidia, with Vipdomet and Incresync combinations.
The brand entered a class already dominated by Januvia, and its late arrival, the third in class, limited commercial traction. Takeda never disclosed blockbuster-scale sales for Nesina, and the DPP-4 class as a whole began losing relevance as SGLT2 inhibitors and GLP-1 agonists demonstrated cardiovascular and weight-loss benefits.
US patent protection expired in the early 2020s, and generic alogliptin gained FDA approvals from 2023, including from generic-focused manufacturers. Takeda has wound down active promotion of the brand, and as of November 2026 the franchise exists primarily as residual branded sales plus a generic molecule.
Advertisement
About Takeda Pharmaceutical Company
What does Takeda make?
Takeda makes prescription pharmaceuticals across six therapeutic areas: gastroenterology (Entyvio, Dexilant), oncology (Ninlaro, Adcetris), neuroscience (Vyvanse, Trintellix, Rozerem), rare diseases (TAKHZYRO), plasma-derived therapies (GAMMAGARD LIQUID), and immunology. The company has three major pipeline products pending launch: oveporexton for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis.
Is Takeda publicly traded?
Yes, Takeda Pharmaceutical Company Limited is listed on the Tokyo Stock Exchange under ticker 4502 and on the NYSE as an ADR under ticker TAK. The company also trades on the Nagoya, Sapporo, and Fukuoka stock exchanges. The company has a broad institutional and retail shareholder base with no single controlling shareholder.
Who is Takeda's CEO?
Julie Kim serves as CEO-elect, succeeding Christophe Weber, who served as President and CEO since 2014. Kim previously led Takeda's Plasma-Derived Therapies business unit. Weber's leadership included the transformative Shire acquisition in 2019. Kim is expected to outline her longer-term strategy at a capital markets day.
What is Takeda's revenue?
For FY2025 (ended March 31, 2026), Takeda reported revenue of JPY 4,505.7 billion (approximately $28.3 billion), a 1.7% decline at actual exchange rates. Core Operating Profit was JPY 1,172.5 billion (approximately $7.4 billion). The company reported a net loss of JPY 152.4 billion due to additional legal provisions and impairment losses. For FY2026, Takeda forecasts revenue of JPY 4,640.0 billion.
Advertisement
Who founded Takeda?
Takeda was founded in 1781 in Osaka, Japan by Chobei Takeda, who established a business selling traditional Japanese and Chinese medicines. The company has been in continuous operation for over 240 years, making it one of the world's oldest pharmaceutical companies.
Where is Takeda headquartered?
Takeda is headquartered in Tokyo, Japan. The company's global operations span more than 80 countries, with its largest market being the United States. Takeda also has major operations in Europe, Japan, and emerging markets.
How many employees does Takeda have?
Takeda employs approximately 50,000 people worldwide. The company's workforce is distributed across research and development, manufacturing, and commercial operations in more than 80 countries.
What are Takeda's major pipeline products?
Takeda's three leading late-stage assets are oveporexton (for narcolepsy type 1, launching H2 2026 with FDA Priority Review), rusfertide (for polycythemia vera, launching H2 2026 with FDA Priority Review), and zasocitinib (for psoriasis, launching H1 2027). The company also has Phase 3 programs for elritercept, mezagitamab, and TAK-881.
Advertisement
- Founded: 1781
- Headquarters: Tokyo, Japan
- Company Type: Publicly Traded
- Stock: Tokyo Stock Exchange; New York Stock Exchange (ADR): 4502 (TSE); TAK (NYSE ADR)
- Revenue: JPY 4,505.7 billion (FY2025, approximately $28.3 billion)
- Employees: approximately 50,000
Where Is Nesina Made / Based?
- Headquarters: Tokyo, Japan
- Manufacturing / Operations: Japan, United States
Nesina Categories & Tags
Brands Owned by Takeda Pharmaceutical Company
Healthcare PharmaceuticalsAdcetris
Owned by Takeda Pharmaceutical Company
Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.
oncologyantibody-drug-conjugatelymphoma
Healthcare PharmaceuticalsAlofisel
Owned by Takeda Pharmaceutical Company
Prescription stem cell therapy originally approved in Europe for treating complex perianal fistulas in adult Crohn's disease patients, developed by TiGenix and acquired by Takeda.
gastroenterologycrohns-diseasefistula
Healthcare PharmaceuticalsAzasan
Owned by Takeda Pharmaceutical Company
Bausch Health's branded azathioprine tablet (75 mg and 100 mg strengths), distributed by Salix Pharmaceuticals (a division of Bausch Health US, LLC) and manufactured by Alcami Corporation, indicated for renal transplant rejection prevention and severe rheumatoid arthritis, based on the immunosuppressant azathioprine originally developed by Nobel laureate Gertrude Elion at Burroughs Wellcome in the 1950s.
immunosuppressantazathioprinetransplant
Healthcare PharmaceuticalsDexilant
Owned by Takeda Pharmaceutical Company
Prescription proton pump inhibitor (dexlansoprazole) for treating GERD and erosive esophagitis, manufactured by Takeda Pharmaceutical Company.
gastroenterologyacid-refluxgerd
Healthcare PharmaceuticalsEntyvio
Owned by Takeda Pharmaceutical Company
Prescription biologic medication for treating inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Takeda's top-selling product, generating over $5 billion annually.
gastroenterologyinflammatory-bowel-diseasecrohns-disease
Healthcare PharmaceuticalsEnvarsus
Owned by Takeda Pharmaceutical Company
Extended-release tacrolimus tablet for preventing organ rejection in kidney and liver transplant recipients. Marketed by Takeda Pharmaceutical Company.
transplantationimmunosuppressionorgan-rejection
Nesina Ownership: Pros & Cons
Advantages
- +Takeda's global regulatory and distribution infrastructure supported launch
- +Fixed-dose combinations broadened the molecule's utility
- +Once-daily dosing and renal-adjustable labeling gave it a workable profile
Considerations
- -Third-to-market launch behind Januvia capped commercial potential
- -DPP-4 class lost share to SGLT2 inhibitors and GLP-1 agonists
- -Generic competition from 2023 eroded branded economics
- -No meaningful strategic priority within Takeda's current portfolio
- -Limited clinical differentiation versus class peers
Advertisement
Frequently Asked Questions About Nesina
Sources & Further Reading
Advertisement
Competitors to Nesina
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Merck | USA | 2006 | Mass market | Global | All Genders | |
| Astrazeneca | United Kingdom | 2009 | Mass market | Global | All Genders | |
| Boehringer Ingelheim | Germany | 2011 | Mass market | Global | All Genders | |
| Bristol Myers Squibb | USA | 1994 | Mass market | Global | All Genders | |
| Sanofi | France | 2000 | Premium | Global | All-ages |
Learn More About Competitors
Healthcare PharmaceuticalsJanuvia
Owned by Merck & Co.
Prescription diabetes medication for treating type 2 diabetes by increasing insulin secretion, manufactured and marketed by Merck & Co.
diabetestype-2-diabetesdpp-4-inhibitor
Healthcare PharmaceuticalsOnglyza
Owned by AstraZeneca PLC
Saxagliptin DPP-4 inhibitor for type 2 diabetes, acquired outright by AstraZeneca in 2014 and later discontinued in the US and Europe as generics entered the market.
diabetestype-2-diabetesdpp-4-inhibitor
Healthcare PharmaceuticalsTradjenta
Owned by Boehringer Ingelheim
Linagliptin DPP-4 inhibitor for type 2 diabetes, developed by Boehringer Ingelheim and co-marketed with Eli Lilly since its 2011 FDA approval.
diabetestype-2-diabetesdpp-4-inhibitor
Healthcare PharmaceuticalsMetformin
Owned by Bristol Myers Squibb Company
First-line biguanide medication for type 2 diabetes, originally marketed as Glucophage by Bristol-Myers Squibb and now one of the most widely prescribed generic drugs in the world.
diabetestype-2-diabetesbiguanide
Healthcare PharmaceuticalsLantus
Owned by Sanofi
Sanofi's long-acting insulin glargine for type 1 and type 2 diabetes, FDA approved April 2000, that reached peak global sales of $6.4 billion in 2015 before biosimilar competition eroded its market share.
diabetesinsulin-glarginetype-1-diabetes
Competitive Analysis
Market Positioning: Nesina competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Nesina
Looking for brands with different ownership structures? These similar brands are not owned by Takeda Pharmaceutical Company, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsTradjenta
Owned by Boehringer Ingelheim
Linagliptin DPP-4 inhibitor for type 2 diabetes, developed by Boehringer Ingelheim and co-marketed with Eli Lilly since its 2011 FDA approval.
diabetestype-2-diabetesdpp-4-inhibitor
Privately Owned
Tradjenta is privately owned, unlike Nesina which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike Nesina which is under a publicly traded parent company.
Healthcare PharmaceuticalsJardiance
Owned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
pharmaceuticalsprescription-drugsdiabetes
Privately Owned
Jardiance is privately owned, unlike Nesina which is under a publicly traded parent company.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Nesina which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Nesina which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Nesina which is under a publicly traded parent company.
Takeda Pharmaceutical Company Stock Information
Advertisement
Jobs at Takeda Pharmaceutical Company
Latest News About Nesina
Advertisement
Related Articles About Nesina
View more articles
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
Health
Health Insurance Brand Ownership: The Big Players
UnitedHealth is #1 ($112B Q2 revenue, 26% MA share). CVS/Aetna is #3 ($106.1B Q2). Humana is #2 in MA (19.8%). Elevance is #2 by enrollment. Discover health insurance brand ownership. Explore our database.
Who Brands StaffNov 11, 2026
UnitedhealthAetnaCvs Health
Health
Organic Food Brand Ownership: Still Independent?
Annie's is General Mills ($820M). Cascadian Farm is General Mills (since 1999). Stonyfield is Lactalis (via Danone, $875M). Kashi is Kellogg's. Honest Tea was Coca-Cola (discontinued). Explore our database.
Who Brands StaffNov 9, 2026
Organic FoodAnniesCascadian Farm
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization